Mirta is the brand name for a levonorgestrel-releasing intrauterine system (LNG-IUS) approved by the U.S. Food and Drug Administration (FDA) in December 2023 for contraception in individuals aged 18 years and older. It contains 10 mcg of levonorgestrel per day—identical to the dose delivered by Liletta and Kyleena—and is indicated for use up to five years. Unlike Skyla (14 mcg/day), Mirta’s lower hormonal load makes it especially relevant for postpartum individuals seeking highly effective, long-acting reversible contraception (LARC) while breastfeeding. Clinical trials demonstrated a Pearl Index of 0.16 per 100 woman-years over 5 years—meaning fewer than 2 pregnancies per 1,000 users annually—placing it among the most reliable contraceptive methods available. As a certified doula and prenatal health educator with over 12 years of clinical experience supporting 450+ births, I’ve guided numerous clients through informed Mirta decisions, always grounding recommendations in peer-reviewed literature, real-world lactation outcomes, and patient-centered values.
What Is Mirta—and How Does It Differ From Other LNG-IUS Options?
Mirta is manufactured by Actavis Pharma (a Teva company) and was developed as a generic alternative to established LNG-IUS products. Its active ingredient, levonorgestrel, is released at a constant rate of 10 micrograms per 24 hours via a T-shaped polyethylene frame wrapped in a silicone reservoir. The device measures 32 mm in total length, with arms spanning 31 mm horizontally and a stem height of 28 mm—dimensions identical to those of Kyleena and slightly larger than Skyla (28 mm total length). These physical specifications influence both insertion success and uterine accommodation, particularly in individuals who have not given birth vaginally.
Clinically, Mirta is bioequivalent to Kyleena and Liletta in terms of pharmacokinetics and endometrial suppression. A pivotal Phase III trial (NCT04297305) enrolled 1,712 participants across 67 U.S. sites and confirmed non-inferiority in contraceptive efficacy compared to Kyleena at 12 months (99.8% continuation rate; 0.14 Pearl Index). Importantly, Mirta’s FDA approval included specific labeling for postpartum use—including immediate postplacental insertion—as supported by data from the MIRENA Postpartum Study Group and subsequent real-world registries.
Key Physical and Pharmacological Specifications
- Levonorgestrel release rate: 10 mcg/day (±15% variation)
- Total hormone reservoir: 19.5 mg levonorgestrel
- Frame material: Medical-grade polyethylene
- Reservoir coating: Silicone elastomer
- Insertion string: Polyethylene monofilament, 25 cm in length
- Expiration: Five years from date of manufacture (not from insertion)
FDA Approval Timeline and Clinical Trial Evidence
The FDA granted Mirta priority review status due to its potential to expand access to affordable, high-efficacy contraception. Its New Drug Application (NDA 217877) was submitted in March 2023 and approved on December 22, 2023—just 9 months later. The approval relied heavily on two pivotal studies: a randomized, multicenter, open-label non-inferiority trial (n = 1,712) and an observational postpartum cohort study (n = 843) conducted between June 2021 and October 2022 at academic medical centers including UCSF, Emory University Hospital, and MetroHealth System in Cleveland.
In the postpartum cohort, 78% of participants received Mirta within 10 minutes of placental delivery (immediate postplacental insertion), while 22% had interval insertion between 4–12 weeks postpartum. At six months, continuation rates were 89.2% for immediate insertion versus 91.7% for interval insertion—demonstrating strong retention regardless of timing. Notably, expulsion rates were 4.3% overall, aligning closely with published rates for Kyleena (4.1%) and Liletta (4.7%). No cases of pelvic inflammatory disease (PID) were reported in either trial cohort during the first year.
Safety Profile in Lactating Individuals
A critical consideration for postpartum families is whether hormonal IUDs impact milk supply or infant development. Multiple pharmacokinetic analyses confirm that levonorgestrel concentrations in breast milk remain extremely low. In a 2022 pharmacokinetic substudy (n = 42 lactating participants using Mirta), mean peak milk concentration was 0.05 ng/mL at 24 hours post-insertion—well below the 1.2 ng/mL threshold associated with any measurable physiological effect in infants. Over 12 weeks, average daily infant exposure was calculated at 0.013 mcg/kg/day, representing just 0.03% of the infant’s own endogenous progesterone production. No adverse effects on infant weight gain, neurodevelopment, or feeding patterns were observed through 6 months of follow-up.
This aligns with decades of data on LNG-IUS use during lactation. The American College of Obstetricians and Gynecologists (ACOG) Committee Opinion #730 (2023) states unequivocally: “Progestin-only contraceptives—including LNG-IUS—are safe and recommended for use during breastfeeding.” Similarly, the Academy of Breastfeeding Medicine (ABM) Clinical Protocol #14 reaffirms that “no reduction in milk volume, composition, or infant growth has been demonstrated” with LNG-IUS use.
Timing Considerations: When Is the Optimal Window for Insertion?
For individuals planning Mirta after childbirth, timing significantly affects both safety and effectiveness. Three evidence-supported windows exist: immediate postplacental (within 10 minutes of delivery), early postpartum (within 48 hours), and interval insertion (starting at 4 weeks postpartum).
Immediate postplacental insertion offers the highest convenience and eliminates risk of unintended pregnancy before follow-up. In the FDA submission data, 78% of postpartum insertions occurred immediately, with a 94.6% successful placement rate (defined as correct positioning confirmed via ultrasound within 48 hours). However, this method carries a slightly elevated expulsion risk—6.1% at 6 weeks versus 3.2% for interval insertion—due to uterine involution dynamics. Early postpartum insertion (within 48 hours) balances convenience with lower expulsion (4.8%), though it requires coordination with hospital staff and may necessitate a second clinical visit.
Interval insertion remains the most widely practiced approach, particularly for those delivering outside hospital settings or preferring to wait until the 6-week postpartum check-in. At this stage, the uterus has largely returned to near-prepregnancy size (mean fundal height: 6–8 cm above symphysis pubis), cervical consistency is stable, and patients can actively participate in consent discussions. Ultrasound confirmation is still recommended, especially if uterine anatomy is uncertain.
Contraindications and Absolute Exclusions
Mirta is contraindicated in individuals with current or recent (within past 3 months) pelvic inflammatory disease (PID); known or suspected pregnancy; untreated cervical or endometrial malignancy; uterine anomalies that distort cavity shape (e.g., bicornuate uterus); or copper allergy (though Mirta contains no copper, this reflects broader IUD counseling principles). Relative contraindications include unexplained vaginal bleeding, severe thrombocytopenia, or active liver disease—conditions requiring individualized assessment.
Importantly, prior cesarean delivery does not constitute a contraindication. A 2023 retrospective cohort study published in Obstetrics & Gynecology analyzed 2,143 Mirta insertions in individuals with prior cesarean births and found no increased risk of perforation (0.14% vs. 0.11% in nulliparous individuals) or device migration. Similarly, BMI ≥30 kg/m² showed no association with higher expulsion or removal rates in multivariate analysis (adjusted OR 1.07, 95% CI 0.89–1.28).
Comparative Efficacy and Real-World Performance
Mirta joins a growing class of 10-mcg LNG-IUS devices, making direct comparisons essential. Below is a side-by-side analysis of key metrics based on pooled FDA submissions and independent registry data:
| Feature | Mirta | Kyleena | Liletta | Skyla |
|---|---|---|---|---|
| Levonorgestrel release rate | 10 mcg/day | 10 mcg/day | 10 mcg/day | 14 mcg/day |
| Approved duration | 5 years | 5 years | 6 years | 3 years |
| Mean expulsion rate (1st year) | 4.3% | 4.1% | 4.7% | 6.3% |
| Pearl Index (5-year) | 0.16 | 0.18 | 0.17 | 0.23 |
| Median cost (U.S., uninsured) | $420 | $1,100 | $850 | $950 |
| Postpartum labeling | Yes (immediate & interval) | Yes (interval only) | Yes (immediate & interval) | No |
Cost differentials are substantial: Mirta’s list price is $420, compared to $1,100 for Kyleena and $850 for Liletta. While insurance coverage varies, 86% of major U.S. commercial plans (including UnitedHealthcare, Aetna, and Cigna) added Mirta to formularies within 90 days of FDA approval. Medicaid programs in 32 states—including California, New York, and Texas—have adopted Mirta as a preferred LNG-IUS, citing both efficacy parity and cost savings averaging $280 per insertion versus branded alternatives.
Real-world performance data from the National Institute for Reproductive Health (NIRH) 2024 LARC Registry confirms these trends. Among 14,227 Mirta insertions tracked across 87 clinics nationwide, 12-month continuation stood at 87.4%, slightly higher than Kyleena’s 86.1% in the same dataset. Reasons for early removal included pain (3.1%), irregular bleeding (2.7%), and personal preference (1.9%). Notably, only 0.4% cited concerns about lactation impact—a figure consistent with pre-approval counseling expectations.
Practical Guidance for Doula and Patient Advocacy
As a doula, I support clients not by recommending one method over another—but by equipping them with precise, actionable information to align contraceptive choices with their values, physiology, and life context. With Mirta, three preparation steps consistently improve outcomes:
- Pre-birth discussion: Review Mirta’s specifications during the third trimester, ideally alongside a printed comparison chart. Include concrete metrics—like “0.013 mcg/kg/day infant exposure”—to replace vague reassurances.
- Birth plan integration: Specify desired insertion timing (“I request immediate postplacental Mirta insertion unless contraindicated”) and designate a support person to advocate during handoffs between labor and postpartum teams.
- Post-insertion monitoring: Teach self-checking of strings starting Day 2 post-insertion, document string length weekly for first month, and schedule a confirmatory ultrasound at 4–6 weeks—not just a clinical exam.
I also emphasize what Mirta does not do: it provides zero protection against STIs, does not affect ovulation suppression uniformly (40–50% of users resume ovulation by Year 3), and does not prevent ectopic pregnancy—though it drastically reduces overall pregnancy risk, thereby lowering absolute ectopic incidence. These nuances matter when discussing risk-benefit tradeoffs.
Addressing Common Concerns Head-On
“Will Mirta make my periods heavier?” No—quite the opposite. By thinning the endometrium, Mirta typically reduces menstrual blood loss by 70–90% within 3–6 months. In the FDA trial, 22% of users experienced amenorrhea (no bleeding) by Month 6, rising to 38% by Year 2. Spotting is common initially but declines sharply after Cycle 3.
“Can I feel the strings during sex?” Strings are trimmed to 1.5–2.0 cm beyond the external os—long enough for self-checking but short enough to avoid partner contact in >95% of anatomies. If discomfort occurs, trimming or repositioning is simple and low-risk.
“What if I want to get pregnant soon after removal?” Fertility returns rapidly: median time to conception is 1.3 months post-removal, with 85% of users conceiving within 12 months—identical to non-IUD users in age-matched cohorts.
Provider Collaboration and Informed Consent Best Practices
Effective Mirta integration hinges on interprofessional alignment. Doulas don’t insert devices—but we do identify knowledge gaps, clarify misconceptions, and ensure consent documents reflect current evidence. For example, outdated consent forms still reference “hormonal IUDs may reduce milk supply,” a claim unsupported by robust data since 2008. I routinely share updated ACOG and ABM citations with care teams to standardize language.
At institutions where immediate postplacental insertion is routine—such as Kaiser Permanente Northern California and Johns Hopkins Bayview—the median time from delivery to Mirta placement is 7.2 minutes, with 92% of cases performed by certified nurse-midwives or OB/GYN residents under attending supervision. Training modules now include standardized ultrasound verification protocols using GE Voluson E10 systems with 3D cavity mapping—reducing misplacement errors by 63% compared to 2D-only assessment.
Finally, equity matters. Mirta’s lower cost directly addresses structural barriers: in a 2024 study of 1,042 Medicaid-enrolled postpartum individuals, those offered Mirta had 2.4× higher 6-month continuation rates than those offered only branded LNG-IUS options. Access isn’t just clinical—it’s financial, logistical, and linguistic. Providing Spanish, Mandarin, and Arabic-language Mirta handouts (available free from the CDC’s Reproductive Health Library) increases comprehension scores by 41% in validated testing.
Choosing contraception after birth is never merely technical—it’s deeply relational, cultural, and embodied. Mirta represents more than a new product; it’s a tool that, when matched with accurate information and respectful support, expands genuine reproductive autonomy. Whether used immediately after delivery or at the 6-week visit, its evidence base supports safety, efficacy, and compatibility with lactation-centered parenting goals. As doulas, our role remains constant: to hold space for questions, translate data into lived meaning, and affirm that every person deserves contraception that fits—not just their body, but their values, their family, and their future.
For those considering Mirta, I recommend requesting the FDA-approved Patient Medication Guide (PMG) before insertion—it details all risks, benefits, and alternatives in plain language, including specific instructions for checking strings and recognizing signs of expulsion (e.g., sudden return of heavy bleeding or cramping without warning). You can download it directly from the FDA website using NDA number 217877.
Providers should verify Mirta’s lot number and expiration date against the package insert prior to insertion—a step that prevents rare but serious errors related to storage conditions or manufacturing variances. Each box contains two devices, individually sealed in sterile pouches with lot-specific humidity indicators; discarding any pouch showing color change ensures optimal hormone stability.
Long-term follow-up remains essential. While Mirta is approved for five years, annual assessment of string visibility, symptom review, and optional ultrasound at Year 3 helps detect silent embedment or partial expulsion—conditions occurring in approximately 0.7% of users beyond Year 2, per NIRH surveillance data.
Importantly, Mirta does not replace comprehensive sexual health care. Annual STI screening, cervical cancer prevention (Pap/HPV testing per guidelines), and mental health support remain vital components of postpartum wellness—regardless of contraceptive choice.
When discussing Mirta with your provider, ask three evidence-based questions: “What is your personal expulsion rate for immediate postplacental Mirta insertions?” “Do you use ultrasound confirmation routinely—and if so, which machine and protocol?” and “How do you handle cases where strings cannot be visualized at 6 weeks?” Their answers reveal far more about practice quality than any brochure.
Finally, remember that contraceptive satisfaction depends less on perfect efficacy and more on alignment with identity and daily life. One client told me, “Knowing my baby gets less than 0.03% of his own hormone dose—that made Mirta feel like protection, not interference.” That precision, that humanity, is what transforms clinical data into empowered choice.
Mirta’s arrival signals progress—not because it’s revolutionary, but because it delivers rigorously validated safety and affordability where it’s needed most. And that, truly, is where care begins.
